Biotechnology company CytoDyn Inc. (CYDY.OB) announced Monday that it has filed with the U.S. Food and Drug Administration (FDA) a request seeking Priority Review designation for its Biologics License Application (BLA) for leronlimab as a combination therapy for HIV indication.
from RTT - Biotech https://ift.tt/3dom7L9
via IFTTT
No comments:
Post a Comment